BioNexus Gene Lab Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 16 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Consolidated Revenue Annually7.4M
Chemrex Segment Revenue Contribution Annually1.0
MRNA Scientific Segment Revenue Contribution Annually0.0
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 per share for 30 consecutive business daysAction: Implement reverse stock split or request compliance extensions to maintain listing on the Nasdaq Capital Market.
- Chemrex Subsidiary Internal Controls and Governance RemediationTrigger: Identification of unauthorized transactions or lapses in corporate governance standardsAction: Conduct comprehensive Audit Committee reviews, reject unauthorized transactions, and restructure subsidiary governance.
- VitaGuard Minimal Residual Disease (MRD) Platform CommercializationTrigger: Transition from development-stage technology to regional deployment in Southeast AsiaAction: Execute strategic licensing agreements, appoint commercial leadership, and integrate the platform into routine oncology workflows.
Research as of 20 Jun 2026